The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Medlab, Inc.; Pinnacle Holdings, Inc.; Metabolic Research Associates, Inc.; USA Health, Inc.; et al.
20090541: Aquiline Financial Services Fund L.P.; Swiss Reinsurance Company Ltd.
20090537: Communications Infrastructure Investments, LLC; FiberNet Telecom Group, Inc.
0906010 Informal Interpretation
0906011 Informal Interpretation
20090526: Golden Gate Capital Opportunity Fund, L.P.; Aeon Co. Ltd.
20090512: Sumitomo Metal Mining Co., Ltd.; Teck Resources Limited
20090505: Valline S.r.l.; Cornerstone Therapeutics Inc.
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
0906009 Informal Interpretation
Liberty Media Corporation and John C. Malone, United States of America (for the Federal Trade Commission)
John C. Malone, CEO and Chairman of Discovery Holding Company, agreed to pay a $1.4 million civil penalty to settle Federal Trade Commission charges that he violated the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with acquisitions of Discovery shares in 2005 and 2008. The FTC alleged that Malone failed to file the required notice in 2005 after buying Discovery shares, and then in 2008 purchased additional Discovery shares before the expiration of a waiting period required by the HSR Act.
CVS Caremark Corporation, In the Matter of
20090532: S. Kumars Nationwide Ltd.; Hartmarx Corporation
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.